SI0761650T1 - Thermally stable and storable crystalline modification of N-methyl-N-((1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1-yl)-ethyl)-2,2-diphenyl-acetamide and process for its preparation - Google Patents

Thermally stable and storable crystalline modification of N-methyl-N-((1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1-yl)-ethyl)-2,2-diphenyl-acetamide and process for its preparation

Info

Publication number
SI0761650T1
SI0761650T1 SI9630392T SI9630392T SI0761650T1 SI 0761650 T1 SI0761650 T1 SI 0761650T1 SI 9630392 T SI9630392 T SI 9630392T SI 9630392 T SI9630392 T SI 9630392T SI 0761650 T1 SI0761650 T1 SI 0761650T1
Authority
SI
Slovenia
Prior art keywords
hydroxypyrrolidin
storable
acetamide
diphenyl
phenyl
Prior art date
Application number
SI9630392T
Other languages
English (en)
Slovenian (sl)
Inventor
Inge Dr. Stein
Holger Beeres
Klaus Dr. Beschmann
Steffen Dr. Neuenfeld
Andrew Dr. Barber
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of SI0761650T1 publication Critical patent/SI0761650T1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
SI9630392T 1995-08-26 1996-08-02 Thermally stable and storable crystalline modification of N-methyl-N-((1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1-yl)-ethyl)-2,2-diphenyl-acetamide and process for its preparation SI0761650T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19531464A DE19531464A1 (de) 1995-08-26 1995-08-26 N-Methyl-N-[(1S-)-1-phenyl-2-((3S)-3-hydroxypyrrolidin 1-yl-)-ethyl]-2,2-diphenyl-acetamid
EP96112489A EP0761650B1 (de) 1995-08-26 1996-08-02 Thermostabile und lagerfähige Kristallmodifikation von N-Methyl-N-((1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1-yl)-ethyl)-2,2-diphenyl-acetamid und Verfahren zu dessen Herstellung

Publications (1)

Publication Number Publication Date
SI0761650T1 true SI0761650T1 (en) 2002-04-30

Family

ID=7770485

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9630392T SI0761650T1 (en) 1995-08-26 1996-08-02 Thermally stable and storable crystalline modification of N-methyl-N-((1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1-yl)-ethyl)-2,2-diphenyl-acetamide and process for its preparation

Country Status (25)

Country Link
US (1) US6060504A (xx)
EP (1) EP0761650B1 (xx)
JP (3) JP5023273B2 (xx)
KR (1) KR100436254B1 (xx)
CN (1) CN1081631C (xx)
AR (1) AR004679A1 (xx)
AT (1) ATE207895T1 (xx)
AU (1) AU716615B2 (xx)
BR (1) BR9603540A (xx)
CA (1) CA2184049C (xx)
CZ (1) CZ287783B6 (xx)
DE (2) DE19531464A1 (xx)
DK (1) DK0761650T3 (xx)
ES (1) ES2165948T3 (xx)
HU (1) HU226667B1 (xx)
MX (1) MX9603606A (xx)
NO (1) NO307048B1 (xx)
PL (1) PL187691B1 (xx)
PT (1) PT761650E (xx)
RU (1) RU2174976C2 (xx)
SI (1) SI0761650T1 (xx)
SK (1) SK282437B6 (xx)
TW (1) TW513407B (xx)
UA (1) UA41978C2 (xx)
ZA (1) ZA967200B (xx)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999032096A1 (en) * 1997-12-22 1999-07-01 Alza Corporation Novel formulations for the transdermal administration of asimadoline
DE19827633A1 (de) * 1998-04-20 1999-10-21 Merck Patent Gmbh Verfahren zur Herstellung von enantiomerenreinem N-Methyl-N-[(1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1-yl)ethyl]-2,2-diphenylacetamid
US6174878B1 (en) * 1999-08-31 2001-01-16 Alcon Laboratories, Inc. Topical use of kappa opioid agonists to treat otic pain
DE10116978A1 (de) * 2001-04-05 2002-10-10 Merck Patent Gmbh Kappa-Opiatagonisten für die Behandlung von Erkrankungen der Blase
EP1505974B1 (en) * 2002-05-17 2009-04-22 Tioga Pharmaceuticals, Inc. Use of compounds that are effective as selective opiate receptor modulators
DE10259245A1 (de) * 2002-12-17 2004-07-01 Merck Patent Gmbh Derivate des Asimadolins mit kovalent gebundenen Säuren
WO2005046687A1 (en) * 2003-10-30 2005-05-26 Tioga Pharmaceuticals, Inc. Use of selective opiate receptor modulators in the treatment of neuropathy
ES2393815T3 (es) 2007-03-30 2012-12-28 Tioga Pharmaceuticals, Inc. Agonistas opioides kappa para el tratamiento de síndrome del intestino irritable con diarrea predominante y alternante
EP2284987B1 (en) * 2009-08-12 2019-02-06 Braun GmbH Method and device for adjusting the frequency of a drive current of an electric motor
WO2011136905A2 (en) * 2010-04-07 2011-11-03 Onyx Therapeutics, Inc. Crystalline peptide epoxyketone immunoproteasome inhibitor
US9675587B2 (en) 2013-03-14 2017-06-13 Allergan Holdings Unlimited Company Opioid receptor modulator dosage formulations
CN103664727A (zh) * 2013-12-19 2014-03-26 无锡万全医药技术有限公司 一种一锅法制备1-[(3s)-3-羟基吡咯烷-1-基]-(2s)-2-甲氨基-2-苯基乙烷的工艺
ES2906979T3 (es) * 2016-12-21 2022-04-21 Tioga Pharmaceuticals Inc Formulaciones farmacéuticas sólidas de asimadolina
EP3932390A1 (en) 2020-07-02 2022-01-05 Dr. August Wolff GmbH & Co. KG Arzneimittel Topical gel formulation containing asimadoline

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4215213A1 (de) * 1992-05-09 1993-11-11 Merck Patent Gmbh Arylacetamide

Also Published As

Publication number Publication date
KR970010744A (ko) 1997-03-27
TW513407B (en) 2002-12-11
DK0761650T3 (da) 2002-02-18
JP5023273B2 (ja) 2012-09-12
HUP9602346A2 (en) 1997-09-29
AU6214996A (en) 1997-03-06
MX9603606A (es) 1997-03-29
HU9602346D0 (en) 1996-10-28
AR004679A1 (es) 1999-03-10
EP0761650A1 (de) 1997-03-12
CZ243496A3 (en) 1997-03-12
DE59608050D1 (de) 2001-12-06
JPH09110830A (ja) 1997-04-28
NO963526L (no) 1997-02-27
PL315799A1 (en) 1997-03-03
RU2174976C2 (ru) 2001-10-20
ES2165948T3 (es) 2002-04-01
HU226667B1 (en) 2009-06-29
EP0761650B1 (de) 2001-10-31
SK108996A3 (en) 1997-06-04
BR9603540A (pt) 1998-05-12
AU716615B2 (en) 2000-03-02
PL187691B1 (pl) 2004-09-30
PT761650E (pt) 2002-04-29
ATE207895T1 (de) 2001-11-15
JP2012246321A (ja) 2012-12-13
JP2009046501A (ja) 2009-03-05
US6060504A (en) 2000-05-09
CZ287783B6 (en) 2001-02-14
UA41978C2 (uk) 2001-10-15
CN1151986A (zh) 1997-06-18
CA2184049C (en) 2007-10-02
CN1081631C (zh) 2002-03-27
NO307048B1 (no) 2000-01-31
NO963526D0 (no) 1996-08-23
KR100436254B1 (ko) 2005-01-25
DE19531464A1 (de) 1997-02-27
SK282437B6 (sk) 2002-02-05
CA2184049A1 (en) 1997-02-27
ZA967200B (en) 1997-03-03
HUP9602346A3 (en) 1998-01-28

Similar Documents

Publication Publication Date Title
SI0761650T1 (en) Thermally stable and storable crystalline modification of N-methyl-N-((1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1-yl)-ethyl)-2,2-diphenyl-acetamide and process for its preparation
HUP9802422A3 (en) Substituted isoquinoline-3-carboxamide derivatives, process for producing them and pharmaceutical compositions containing them
PL317595A1 (en) 1-phenyl-2-dimethylaminomethylcyclohexanol-1 compounds, method of obtaining them and pharmaceutic preparation
AU4015597A (en) Process for producing bone cement containing active substances
AU7562296A (en) Novel amino acid derivatives, methods of producing them, and pharmaceutical compounds containing these compounds
CZ58196A3 (en) Naphthyl derivative, process of its preparation, pharmaceutical composition containing and intermediate for preparing thereof
HUP9800295A3 (en) Substituted heterocyclic compounds, preparation method therefor and pharmaceutical compositions containing same, intermediates of them
PL309100A1 (en) Protamino insulin complex, pharmaceutical composition containing such complex and method of obtaining same as well as obtaining crystalline protamino insulin
PL318277A1 (en) Novel substituted axazolydinones, method of obtaining and drugs containing them
HU9600680D0 (en) Benzazepine,-benzoxazepine- and benzothiazepine-n-acetic acid derivatives, process for producing them, and pharmaceutical composition containing them
HUP9802578A3 (en) Phenylacetic acid derivatives, process and intermediates for producing them, fingicide, insecticide, arachnicide and nematocide compositions containing these compounds as active ingredients and use thereof
PL317985A1 (en) Heteroatoms containing cyclopentanopyridynyl oxazolydinones, method of obtaining and drugs containing them
PL318278A1 (en) Novel heteroaryl oxazolydinones, method of obtaining and drugs containing them
AU1912197A (en) New inhibitors of metalloprotease, process for preparing them and pharmaceutical compositions containing them
AU9002598A (en) Nitrogenous fused-ring compounds, process for the preparation of the same, and drugs
PL312270A1 (en) Novel derivatives of indolopiperidine, method of obtaining them and pharmaceutical preparation and method of obtaining same
PL313632A1 (en) Novel compounds, method of obtaining them as well as pharmaceutic preparation and method of obtaining same
AU5108196A (en) Imidazoquinazolines, drugs containing these compounds, their use and process for their preparation
HUP0003053A3 (en) Crystalline forms of 33-epichloro-33-desoxyascomycin, process for their preparation and pharmaceutical compositions containing them
GB9617893D0 (en) New pharmaceutical derivatives, process for obtaining them and pharmaceutical compositions containing them
AU3768097A (en) Catalytic preparation process of n-acylglycine derivatives
HU9303030D0 (en) Process for preparation of l-5-(2-acetoxi-propionyl-amino)-2,4,6-trijodo-dichloro-isophtalic acid
AU5168496A (en) Butyryl-tyrosinyl spermine, analogs thereof and methods of preparing and using same
HUP9701921A3 (en) Heterocyclic amino-methyl compounds, process for producing them, and pharmaceutical compositions containing them
HUP0100785A3 (en) Indole derivatives, process for producing them and pharmaceutical compositions containing them